Literature DB >> 7957446

Influence of renal function on the pharmacokinetics of diacerein after a single oral dose.

P Debord1, K Louchahi, M Tod, A Cournot, G Perret, O Petitjean.   

Abstract

The pharmacokinetics of diacetylrhein following a single oral dose of 50 mg was studied in 12 healthy volunteers and two groups of 8 patients with mild or severe renal insufficiency. Statistical analysis using a Kruskal-Wallis rank sum test showed a significant difference between the three groups for the following parameters. In severely uraemic patients, median AUC0-infinity was multiplied by a factor of about 2: 40.5 mg.h/l versus 21.3 mg.h/l in healthy subjects, P = 0.04; and t1/2 was prolonged by the same factor: 9.6 h versus 4.3 h in the control group, P = 0.003. Apparent drug availability and renal clearance assessed through urinary data decreased with renal failure, respectively: 14.5% and 0.045 l/h versus 35.4% (P = 0.01) and 0.13 l/h (P = 0.008) in healthy subjects. Amounts of glucuro- and sulpho-conjugates in urine were lower in severely uraemic patients. Intermediate values were observed for mildly uraemic patients. Other parameters: lag time, Cmax, tmax, Vss/F, urinary glucuro- to sulpho-conjugate ratios did not change significantly. Apparent total clearance of rhein was poorly correlated with creatinine clearance and this was related to a decrease of non-renal clearance of rhein in renal insufficiency. It was concluded that, from a pharmacokinetic point of view, a reduction (50%) in the initial dosage of diacerein should be considered in severe renal failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957446     DOI: 10.1007/BF03188817

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  Pharmacokinetics of 14C-labelled rhein in rats.

Authors:  W Lang
Journal:  Pharmacology       Date:  1988       Impact factor: 2.547

2.  Metabolism of 14C-rhein and 14C-rhein anthrone in rats.

Authors:  P de Witte; J Lemli
Journal:  Pharmacology       Date:  1988       Impact factor: 2.547

3.  Clofibrate disposition in renal failure and acute and chronic liver disease.

Authors:  R Gugler; J W Kürten; C J Jensen; U Klehr; J Hartlapp
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

4.  [Biliary elimination of cephaloridine. Pharmacokinetic, experimental and clinical data].

Authors:  J M Brogard; P Haegele; M Dorner; J Lavillaureix
Journal:  Ann Biol Clin (Paris)       Date:  1972       Impact factor: 0.459

5.  Pindolol availability in hypertensive patients with normal and impaired renal function.

Authors:  N P Chau; Y A Weiss; M E Safar; D E Lavene; D R Georges; P L Milliez
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

6.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Furosemide kinetics in renal failure.

Authors:  W J Tilstone; A Fine
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

Review 8.  The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences.

Authors:  J Caldwell; A J Hutt; S Fournel-Gigleux
Journal:  Biochem Pharmacol       Date:  1988-01-01       Impact factor: 5.858

9.  Biliary excretion of a new semisynthetic cephalosporin, cephacetrile.

Authors:  J M Brogard; P Haegele; M Dorner; J Lavillaureix
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

10.  [Diacereine: an original approach in the treatment of degenerative and/or extra-articular rheumatism].

Authors:  M Carrabba; G Mele; M Chevallard; M Angelini
Journal:  Minerva Med       Date:  1987-02-15       Impact factor: 4.806

View more
  4 in total

1.  Effects of sesamin on the biosynthesis of chondroitin sulfate proteoglycans in human articular chondrocytes in primary culture.

Authors:  Peraphan Pothacharoen; Sumet Najarus; Jongkolnee Settakorn; Shuji Mizumoto; Kazuyuki Sugahara; Prachya Kongtawelert
Journal:  Glycoconj J       Date:  2013-12-12       Impact factor: 2.916

Review 2.  Diacerein.

Authors:  C M Spencer; M I Wilde
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway.

Authors:  Lehe Yang; Jifa Li; Lingyuan Xu; Shichong Lin; Youqun Xiang; Xuanxuan Dai; Guang Liang; Xiaoying Huang; Jiandong Zhu; Chengguang Zhao
Journal:  Cancer Manag Res       Date:  2019-02-01       Impact factor: 3.989

4.  Stress degradation studies and development of a validated stability-indicating-assay-method for determination of diacerein in presence of degradation products.

Authors:  Purnima Hamrapurkar; Priti Patil; Masti Desai; Mitesh Phale; Sandeep Pawar
Journal:  Pharm Methods       Date:  2011-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.